Oncotarget

Research Papers:

Molecular regulation of ERK5 in development of diabetic retinopathy

Qi Zhao _, Lin Wang, Yuan Sun and Xiao-Xia Wang

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:1229-1236. https://doi.org/10.18632/oncotarget.23392

Metrics: PDF 1400 views  |   HTML 1804 views  |   ?  


Abstract

Qi Zhao1, Lin Wang1, Yuan Sun1 and Xiao-Xia Wang1

1Department of Ophthalmology, The Second Hospital of Dalian Medical University, Dalian 116023, China

Correspondence to:

Qi Zhao, email: [email protected]

Keywords: diabetic retinopathy (DR); ERK5; streptozocin (STZ); retina neovascularization

Received: November 16, 2017     Accepted: December 01, 2017     Published: December 17, 2017

ABSTRACT

Diabetic retinopathy (DR) is a major complication of diabetes, and causes pathological changes in retina blood vessels, as the most common cause of vision loss. Extracellular-signal-regulated kinase 5 (ERK5) is the newest discovered member in the mitogen-activated protein kinases (MAPKs) family, and recent evidence demonstrates an essential role of ERK5 signaling in the angiogenesis. However, whether ERK5 signaling may regulate DR development is unknown. Here, we used a streptozocin (STZ)-induce mouse DR model to investigate this question. We detected significant increases in the phosphorylation of ERK5, a signature of ERK5 activation in the purified retinal endothelial cells in DR mice, compared to control mice. In vivo suppression of ERK5 phosphorylation through administration of a specific inhibitor of ERK5 activation, BIX02189, did not prevent the occurrence of STZ-induced diabetes in mice, but significantly alleviated the severity of DR, seemingly through attenuating the retina neovascularization. Thus, our study suggests a previously unappreciated role of ERK5 signaling in DR development.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23392